Impact of preceding respiratory viral infections on the clinical severity of patients with pneumococcal pneumonia

Influenza and other Respiratory Viruses

Volumn 8, Issue 5, 2014, Pages 549-556

  Yoon, Young Kyung ^a   Yang, Kyung Sook ^a   Sohn, Jang Wook ^a   Lee, Chang Kyu ^a   Kim, Min Ja ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Streptococcus pneumoniae; Clinical severity; Pneumonia; Respiratory viruses

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM DERIVATIVE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; OSELTAMIVIR; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONAVIRUS INFECTION; DISEASE SEVERITY; FEMALE; HUMAN; HYPOALBUMINEMIA; INFLUENZA A; INFLUENZA B; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METAPNEUMOVIRUS INFECTION; MIDDLE AGED; MIXED INFECTION; OBSERVATIONAL STUDY; PARAINFLUENZA VIRUS INFECTION; PNEUMONIA SEVERITY INDEX; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; RHINOVIRUS INFECTION; RISK ASSESSMENT; RISK FACTOR; STREPTOCOCCUS PNEUMONIA; UNIVERSITY HOSPITAL; UREMIA; VIRAL RESPIRATORY TRACT INFECTION; CLASSIFICATION; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; PNEUMONIA, PNEUMOCOCCAL; RESPIRATORY TRACT INFECTION; SEVERITY OF ILLNESS INDEX; STREPTOCOCCUS PNEUMONIAE; VIROLOGY; VIRUS; YOUNG ADULT;

ADULT; AGED; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STREPTOCOCCUS PNEUMONIAE; VIRUSES; YOUNG ADULT;

EID: 84908054515     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12265     Document Type: Article

References (28)

1. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009; 374:1543-1556.
2. Lieberman D, Schlaeffer F, Boldur I et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51:179-784.
3. Woo JH, Kang JM, Kim YS et al. A prospective multicenter study of community-acquired pneumonia in adults with emphasis on bacterial etiology. Infect Chemother 2007; 33:1-7.
4. Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223-229.
5. Rodriguez A, Lisboa T, Blot S et al. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med 2009; 35:430-438.
6. Saldías PF, Viviani GP, Pulgar BD et al. Prognostic factors and mortality in immunocompetent adult patients hospitalized with community-acquired pneumococcal pneumonia. Rev Med Chil 2009; 137:1545-1552.
7. Song JS, Choe PG, Song KH et al. Risk factors for 30-day mortality in adult patients with pneumococcal bacteraemia, and the impact of antimicrobial resistance on clinical outcomes. Epidemiol Infect 2012; 140:1267-1276.
8. Harboe ZB, Thomsen RW, Riis A et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009; 6:e1000081.
9. Riquelme R, Torres A, El-Ebiary M et al. Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996; 154:1450-1455.
10. Johnstone J, Majumdar SR, Fox JD et al. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008; 134:1141-1148.
11. Templeton KE, Scheltinga SA, van den Eeden WC et al. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005; 41:345-351.
12. Jennings LC, Anderson TP, Beynon KA et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008; 63:42-48.
13. Johansson N, Kalin M, Hedlund J. Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. Scand J Infect Dis 2011; 43:609-615.
14. Gaydos CA. What is the role of newer molecular tests in the management of CAP? Infect Dis Clin North Am 2013; 27:49-69.
15. Senft AP, Taylor RH, Lei W et al. Respiratory syncytial virus impairs macrophage IFN-alpha/beta- and IFN-gamma-stimulated transcription by distinct mechanisms. Am J Respir Cell Mol Biol 2010; 42:404-414.
16. Stark JM, Stark MA, Colasurdo GN et al. Decreased bacterial clearance from the lungs of mice following primary respiratory syncytial virus infection. J Med Virol 2006; 78:829-838.
17. Kukavica-Ibrulj I, Hamelin ME, Prince GA et al. Infection with human metapneumovirus predisposes mice to severe pneumococcal pneumonia. J Virol 2009; 83:1341-1349.
18. Alymova IV, Portner A, Takimoto T et al. The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2005; 49:398-405.
19. Nickerson CL, Jakab GJ. Pulmonary antibacterial defenses during mild and severe influenza virus infection. Infect Immun 1990; 58:2809-2814.
20. Hament JM, Kimpen JL, Fleer A et al. Respiratory viral infection predisposing for bacterial disease: a concise review. FEMS Immunol Med Microbiol 1999; 26:189-195.
21. Tristram DA, Hicks W Jr, Hard R. Respiratory syncytial virus and human bronchial epithelium. Arch Otolaryngol Head Neck Surg 1998; 124:777-783.
22. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250.
23. Longo DL, Fauci AS, Kasper DL et al. Harrison's Principles of Internal Medicine, 18th edn. New York: McGraw-Hill, 2008.
24. Song JH, Jung KS, Kang MW et al. Treatment guidelines for community-acquired pneumonia in Korea: an evidence-based approach to appropriate antimicrobial therapy. Infect Chemother 2009; 41:133-153.
25. Charlson M, Szatrowski TP, Peterson J et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47:1245-1251.
26. Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377-382.
27. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement, M100-S18. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
28. Roh KH, Kim J, Nam MH et al. Comparison of the Seeplex reverse transcription PCR assay with the R-mix viral culture and immunofluorescence techniques for detection of eight respiratory viruses. Ann Clin Lab Sci 2008; 38:41-46.